BioGeneration Ventures et al. invest in Arcarios

The value of the investment has not yet been disclosed. BioGeneration Ventures led the round, and was joined by Crédit Agricole Private Equity, Baekeland, the Erasmus MC Biomedical Fund, the Gemma Frisius Fund, Vinnof, CD3 Leuven and the Tigenix company.

Arcarios focuses on the discovery and development of innovative, disease-modifying products that target bone and joint diseases. Established through a merger of Therosteon B.V. and a spin-off from Tigenix NV, the company employs six people and is based in Rotterdam.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Grégoire Gille on +44 20 7484 9824 or gregoire.gille@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Early-stage
• Healthcare
• Netherlands